Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD

In conclusion, treatment with FC as a phosphate binder results in increased iron parameters apparent after 12 weeks and reduces iv iron and ESA use while maintaining hemoglobin over 52 weeks, with a safety profile similar to that of available binders.

Source: Journal of the American Society of Nephrology : JASN - September 30, 2015 Category: Urology & Nephrology Authors: Umanath, K., Jalal, D. I., Greco, B. A., Umeukeje, E. M., Reisin, E., Manley, J., Zeig, S., Negoi, D. G., Hiremath, A. N., Blumenthal, S. S., Sika, M., Niecestro, R., Koury, M. J., Ma, K.-N., Greene, T., Lewis, J. B., Dwyer, J. P., for the Collaborative S Tags: Clinical Research Source Type: research